The neuropeptides Galanin and Galanin (1-15) in depression-like behaviours by Millón, Carmelo et al.
Millón et al., 2016 Neuropeptides
1
THE NEUROPEPTIDES GALANIN AND GALANIN 
(1-15) IN DEPRESSION-LIKE BEHAVIOURS
Carmelo Millón1*, Antonio Flores-Burgess1, Manuel Narváez1, Dasiel O. 
Borroto-Escuela2, Belén Gago1, Luis Santín3, Estela Castilla-Ortega3, José 
Ángel Narváez1, Kjell Fuxe2 & Zaida Díaz-Cabiale1.
1. Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, 
Facultad de Medicina, Departamento de Fisiología, Campus de Teatinos s/n, 
29071 Málaga, Spain.
2. Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
3. Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, 
Facultad de Psicología, Departamento de Psicobiología, Campus de Teatinos 
s/n, 29071 Málaga, Spain.
*Corresponding author:
Carmelo Millón Peñuela, PhD
 Departamento de Fisiología
 Facultad de Medicina
 Universidad de Málaga
 Campus de Teatinos s/n. 29080 Málaga, Spain 
E-mail: carmelomp@uma.es 
Millón et al., 2016 Neuropeptides
2
Millón et al., 2016 Neuropeptides
3
Abstract
Galanin is a 29 amino acid neuropeptide widely distributed in neurons within the 
central nervous system. Galanin exerts its biological activities through three 
different G protein-receptors and participates in a number of functions, including 
mood regulation. Not only Galanin but also Galanin N-terminal fragments like 
Galanin(1-15) are active at the central level. In this work, we review the latest 
findings in studies on Galanin and Galanin(1-15) in depression-related 
behaviours. Our focus is on animal models for depression, and we pay some 
attention to research data obtained in human studies. Since Serotonin (5-HT), 
especially through 5-HT1A, and Galanin receptors interact at both pre-and 
postsynaptic level, the development of drugs targeting potential GAL1-GAL2-5-
HT1A heteroreceptor complexes linked to the raphe-hippocampal 5-HT neurons 
may represent new treatment strategies in depression.
Key words: depression, galanin
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Introduction
Mood disorders, including depression and anxiety, are among the most 
prevalent mental illnesses with high socioeconomic impact (Gelenberg, 2010; 
Wittchen et al., 2011). Although the underlying mechanisms have not yet been 
clearly defined in the last decade the importance of the role of neuropeptides, 
including Galanin (GAL), and/or their receptors in the treatment of stress-related 
mood disorders is becoming increasingly apparent (Kormos et al., 2013).
GAL is a 29 amino acid neuropeptide (Tatemoto et al., 1983) widely distributed 
in neurons within the central nervous system (CNS) including raphe nuclei, 
cerebral cortex and hippocampus (Jacobowitz et al., 2004) among other nuclei 
involved in mood disorders. Three GAL receptor subtypes (GAL1-3 receptors) 
have been described (Branchek et al., 2000; Mitsukawa et al., 2008). GAL1 and 
GAL2 receptors, in particular, are found in many regions of the CNS as 
demonstrated with in situ hybridization, radioligand binding, and 
immunohistochemical studies (Jacobowitz et al., 2004) and have all high affinity 
for GAL. GAL1 and GAL3 receptors mainly activate inhibitory G proteins Gi/Go, 
while GAL2 receptor primarily couples to Gq/G11 to mediate excitatory signaling 
(Branchek et al., 2000).
The three GAL receptors participate in a number of functions in the CNS 
including neuroendocrine levels, mood regulation, pain control, cardiovascular 
functions, addiction and food intake (Lu et al., 2007; Kuteeva et al., 2008; 
Mitsukawa et al., 2008; Diaz-Cabiale et al., 2010; Juhasz et al., 2014; Lang et 
al., 2015)
Not only GAL but also the GAL fragments like GAL N-terminal fragment 1-15 
[GAL(1-15)] are active in the CNS (Hedlund et al., 1996; Diaz-Cabiale et al., 
2005; Diaz-Cabiale et al., 2010; Millon et al., 2015; Millon et al., 2016). 
Structure-activity studies described that in the brain, N-terminal fragments of 
GAL are biologically active, whereas C-terminal fragments are inactive (Diaz-
Cabiale et al., 1998)  and they act as agonists in several physiological functions 
(Diaz-Cabiale et al., 1998; Diaz-Cabiale et al., 2005), suggesting a receptor-
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mediated action. Although the three GAL receptors subtypes show higher 
affinity for GAL than for GAL(1-15) (Branchek et al., 1998), the presence of 
specific binding sites for this GAL fragment in the CNS also in areas lacking 
[125I]- GAL binding sites indicated a powerful role of GAL fragments, especially 
in the dorsal hippocampus, neocortex and striatum (Hedlund et al., 1992). Only 
GAL(1-15), but not GAL, can antagonically modulate the serotonin 5-HT1A 
receptors in the dorsal hippocampus, and this effect was blocked by the GAL 
receptor antagonist M35 (Hedlund et al., 1994). In the ventral limbic cortex, N-
terminal GAL fragments can more stringy and more potently reduce 
posjunctionals 5-HT1A receptor recognition than GAL, where high-affinity GAL 
receptors also exist (Diaz-Cabiale et al., 2000; Diaz-Cabiale et al., 2010). The 
formation of GAL1/GAL2 heteroreceptors highly specific for GAL fragments will 
explain the different effects between GAL and GAL(1-15) (Fuxe et al., 2008; 
Fuxe et al., 2012; Millon et al., 2015).
In this work, we review the latest findings in studies on GAL and GAL(1-15) in 
depression-related behaviours. Our focus is on animal models for depression, 
and we pay some attention to research data obtained in human studies.
GALANIN IN DEPRESSION
A major impediment in depression research is the lack of validated animals´ 
models. Animals not only lack consciousness of self, self-reflection and 
consideration of others but also hallmarks of the disorder such as depressed 
mood, low self esteem or suicidal intent are hardly accessible in non-human 
(Deussing, 2006). However, depression, as other mental disorders, constitutes 
of intermediate or so-called endophenotypes that can be reproduced 
independently and evaluated in animals, including physiological, 
endocrinological and neuroanatomical alterations as well as behavioural traits. 
Numerous behavioural paradigms have been established to elucidate face and 
construct validity of depression models, including antidepressant-screening test 
(Deussing, 2006). 
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The forced swimming test (FST), the most used paradigm to assess 
depression- and antidepressant- like behaviour, also known as the ‘behavioural 
despair’ test, was developed by Porsolt et al. (Porsolt et al., 1977) as a rodent 
model for predicting the clinical efficacy of antidepressant drugs (Bogdanova et 
al., 2013). The FST takes advantage of the observation that rodents, following 
initial escape-oriented movements, rapidly adopt a characteristic immobile 
posture in an inescapable cylinder filled with water. In this paradigm, immobility 
is interpreted as a passive stress-coping strategy or depression-like behaviour 
(behavioural despair) (Deussing, 2006). 
Fuxe´s Laboratory, around nineties, reported the first evidence of the 
involvement of GAL in depression. In animal models, GAL administered into the 
lateral ventricle (i.c.v) reduced serotonin (5-HT) metabolism in ventral limbic 
cortex, hippocampal formation, and fronto-parietal cortex probably via direct 
inhibitory actions on dorsal raphe (DR) 5-HT nerve cells reducing their firing 
rates (Fuxe et al., 1988b). These results suggested based on the 5-HT 
hypothesis of depression that GAL, may contribute to depression by reducing 
firing in the ascending 5-HT neurons (Fuxe et al., 1988b).
GAL in the rat ventral tegmental area (VTA) induced in a dose-dependent 
manner an increased in immobility time in the FST (Weiss et al., 1998), an 
effect that was blocked by the coinfusion of the GAL receptor antagonist M35. 
I.c.v. GAL also resulted in an increase of immobility time in FST confirming that 
GAL may induce depression-like phenotype (Kuteeva et al., 2007). In the rat, 
intraperitoneal injection of galnon or galmic, GAL receptor agonists, reduced 
immobility time in the rat FST, indicating an antidepressant-like effect of 
systemically GAL receptor agonists (Bartfai et al., 2004; Lu et al., 2005) (Table 
1).
The role of GAL in depression-like behaviour has been analysed in genetically 
modified mice. Mice over-expressing GAL under the platelet-derived growth 
factor-B promoter (GalOE-P) displayed an increased immobility in the FST, 
suggesting a depression-like behaviour (Kuteeva et al., 2005; Kuteeva et al., 
2008). However, Holmes et al. (2005) (Holmes et al., 2005) failed to show such 
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alterations in GAL over-expressing mice under the dopamine-β-hydroxylase 
promoter (GalOE-D) and GAL1 receptor knockout (KO) mice (Table 1). 
Importantly, GalOE-P but not GalOE-D mice showed an augmentation of 
hippocampal noradrenaline (NA) and 5-HT release probably indicating that the 
mechanisms underlying the increase of immobility in GalOE-P can be related to 
modulation of NA and 5-HT transmission.
In a genetic rat model of depression, the Flinder sensitive line, which displays a 
high immobility in FST, an up-regulation of the GAL receptor binding sites, is 
found in the DR, and reduces GAL fiber density in the hippocampus and 
hypothalamus. The results indicate that enhancement of GAL receptors function 
in the DR rich in 5-HT neurons could be a mechanism involved in the production 
of depressive-like activity in this animal model of depression (Bellido et al., 
2002). 
Galanin Receptors in depression
Several studies suggest that GAL1/GAL3 receptors can contribute to the pro-
depressive effect of GAL. I.c.v infusion of GAL1 receptor agonist (M617) 
elevated the immobility time in the FST, similar to GAL itself. Moreover, the 
depression-like behavior in rats exposed to chronic mild stress was related to 
an elevated expression of GAL1 receptor in the ventral periaqueductal gray 
(Wang et al., 2016). Furthermore, administration of GAL3 receptor antagonists 
to rat and mice produced antidepressant-like effects in both FST and the tail 
suspension test (TST) (Swanson et al., 2005; Barr et al., 2006) (Table 1). The 
TST is another prominent test, which relies on similar assumptions and 
interpretations as the FST (Steru et al., 1985). In the TST, animals are 
suspended by their tails for a defined period of time, and their immobility is 
assessed (Deussing, 2006). 
Stimulation of the GAL2 receptor, in contrast, produces antidepressant-like 
effects. The i.c.v. GAL2 receptor agonist AR-M1896 decreased the immobility 
time in the FST, while the GAL2 receptor antagonist (M871) elevated the 
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immobility time in the FST (Kuteeva et al., 2008). Recent studies shown that 
systemically active GAL2 receptor agonist reduced the immobility time in the 
FST and in the TST, confirming the potential antidepressant effect of GAL2 
receptor (Saar et al., 2013b; Saar et al., 2013a) (Table 1).
GAL1 receptor (Holmes et al., 2003), GAL3 receptor (Brunner et al., 2014) and 
GAL2 receptor (Bailey et al., 2007) null mutant displayed an anxiogenic-like 
phenotype in the elevated plus maze; nevertheless, neither GAL1 receptor 
knockout (Holmes et al., 2005) nor GAL2 receptor knock out (Gottsch et al., 
2005) mice differed from their wild-type littermate in the TST. On the contrary, 
transgenic mouse over-expressing GAL2 receptor-enhanced, green fluorescent 
protein constructed under the platelet-derived growth factor-B promotor 
decreased levels of immobility in the FST (Le Maitre et al., 2011). GAL3 
receptor knock out mice displayed a trend toward decreased immobility time in 
the TST, indicating a reduction in depression-like behaviour (Brunner et al., 
2014) (Table 1).
All these results indicate that stimulation of GAL2 receptor may be responsible 
for antidepressant-like effects, whereas GAL1 and GAL3 receptors seem to 
contribute to the prodepressive effects of GAL.
In addition, both chronic treatments with the selective serotonin reuptake 
inhibitor (SSRI) fluoxetine and electroconvulsive treatment increase GAL mRNA 
levels in the DR of the rat, accompanied by an increase in GAL2 receptor, but 
not GAL1 receptor, binding sites in this monoaminergic nuclei. Moreover, co-
administration of GAL receptors antagonist M40 blocked the behavioural effect 
of fluoxetine in the FST, suggesting that the antidepressant action of fluoxetine 
can, at least partially, be related to an increase in GAL-mediated transmission 
(Lu et al., 2005; Kuteeva et al., 2008). Yamada and co-workers found that after 
four-week treatment with sertraline, a SSRI, GAL but not GAL2 receptor was 
upregulated in the ventral dentate gyrus (Yamada et al., 2013).  Moreover, the 
chronic administration of desipramine, a tricyclic antidepressant, paroxetine, a 
SSRI, and phenelzine, a monoamine oxidase inhibitor, affected mRNA for GAL 
and GAL receptors (Rovin et al., 2012). In the VTA, the most marked change in 
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mRNA produced by these drugs was a decrease in mRNA for GAL2 receptor 
(Rovin et al., 2012). However, Venlafaxine, a selective serotonin and 
noradrenalin reuptake inhibitor, does not alter transcript levels of GAL or its 
three receptors (Petschner et al., 2016). These results suggest that the effects 
on GAL and GAL receptors are not uniform among antidepressants and may be 
related to certain pharmacological properties (Petschner et al., 2016).
Some human data support the involvement of GAL and its receptors in mood 
disorders. Thus, GAL given intravenously induced antidepressant-like effects, 
indicated by a suppression of REM sleep in healthy male volunteers (Murck et 
al., 2004). Recently in a genome wide screening, the single nucleotide 
polymorphism of GAL gene has been associated with major depression (Wray 
et al., 2012). Moreover, a work reported that variants in genes for GAL, and its 
receptors confer an increased risk of depression and anxiety in people who 
experienced childhood adversity or recent negative life events (Juhasz et al., 
2014). Furthermore, significant positive correlation between plasma GAL level 
and depression severity has been demonstrated suggesting that plasma GAL 
levels may be an important biomarker for depression (Wang et al., 2014). 
Recent findings showed that GAL, GAL1 and GAL3 receptors mRNA levels were 
increased in DR nucleus and GAL and GAL3 receptor in Locus Coeruleus (LC) 
in brains from depressed persons who had committed suicide (Barde et al., 
2016).
All these studies suggest the importance of GAL and its receptors in the 
pathogenesis of depression.
GALANIN(1-15) IN DEPRESSION
We have analysed the role of GAL(1-15) on the depression-like behaviour using 
two tests, the FST and the TST.
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In the FST, i.c.v. GAL(1-15) 3 nmol significantly increased the immobility time 
and decreased the time of climbing by 44% and 46% respectively. In addition, 
this effect was shown with the administration of GAL(1-15) 6 nmol (Millon et al., 
2015). The same pattern of response was observed in the TST, GAL(1-15) at 
the dose of 3 nmol also significantly increased the immobility behaviour 
recorded during the 6 min of testing (Millon et al., 2015) (Table 1). 
These results in both behavioural tests suggest that GAL(1-15) could evoke a 
strong depression-like behaviour.
When we compared the effects in FST induced by GAL and GAL(1-15), we 
observed that the increase in the immobility induced by GAL(1-15) was 
significantly higher than the one induced by GAL (Millon et al., 2015). Moreover, 
in climbing behaviour, GAL(1-15) also induced a stronger decrease in climbing 
response compared with GAL (Millon et al., 2015).
In the open field test and in the light-dark box (Prut et al., 2003), we observed 
that only GAL(1-15) and not GAL modifies the anxiety parameters (Millon et al., 
2015) (Table 1). GAL produced anxiolytic-like effects only in animals tested 
under heightened stress conditions (Barrera et al., 2005; Millon et al., 2015), on 
contrary, GAL(1-15) induced an anxiogenic-like effect without a stress situation 
(Millon et al., 2015).
All these results confirm an important role of GAL(1-15) in mood disorders.
Galanin Receptors involved in GAL(1-15)-mediated effect: siRNA GAL1 
receptor or GAL2  receptor Knockdown rats.
Gene silencing by RNA interference is as a new method of inhibiting the 
expression of targeted genes and inducing knockdown of associated proteins 
both in vitro and in vivo (Nakajima et al., 2012). This RNA interference has been 
applied in experimental investigations in the treatment of illnesses, including 
neuropsychiatric disorders (Nakajima et al., 2012). Dharmacom Accell siRNA is 
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one type of naked siRNA modified chemically resulting in robust silencing of 
selected genes and knockdown of associated proteins (Nakajima et al., 2012). 
We used the Accell siRNA system for generating GAL1 or GAL2 receptors 
knockdown (KD) rats to analyze the involvement of GAL receptors in GAL(1-
15)-mediated effects.
Rats were i.c.v. injected with 5 μg of Accell Smart pool siRNA GAL1 receptor or 
siRNA GAL2 receptor (Dharmacom), or 5 μl of vehicle (Accell siRNA Delivery 
Media). We have analysed the reduction produced by siRNAs with a time-
course curve performed in siRNA GAL2 or GAL1 receptors animals and we 
examined the mRNA for GAL2 and GAL1 receptors in the dorsal hippocampus 
by real-time quantitative polymesare chain reaction (RT-PCR) in these animals.
In figure 1A, it is shown that a single injection of siRNA GAL2 receptor induced a 
strong reduction of mRNA GAL2 receptor (p<0.05) at day 4 and 6 after siRNA 
treatment (Millon et al., 2015). However, the icv injection of siRNA GAL2 
receptor lacked effect in mRNA GAL1 receptor expression (Fig. 1B) 
[unpublished results]. 
The single injection of siRNA GAL2 receptor produced the strongest decreased 
in the receptor expression 8 days after the injection by 35 % in CA1 of the 
dorsal hippocampus and by 50% in piriform cortex (Millon et al., 2015).
The same pattern of response in mRNA expression was shown after the 
administration of siRNA GAL1 receptor. A strong reduction of mRNA GAL1 
receptor at 8 days (p<0.001) was produced by siRNA GAL1 receptor (Fig. 1C) 
(Millon et al., 2015). Again, the Accell siRNA system is specific, since that 
injection of siRNA GAL1 receptor did not modify the mRNA GAL2 receptor 
expression (Fig. 1D) [unpublished results].
The Down-regulation of GAL2 or GAL1 receptors did not affect any parameters 
in the FST or in the open field test (OFT) (Table 1). However, this decrease in 
GAL2 or GAL1 receptors was enough to block the depression- and anxiogenic-
like effect of GAL(1-15) in both tests (Millon et al., 2015). Thus, GAL(1-15) at 
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the dose of 3 nmol lacked effect on immobility, climbing and swimming time in 
the FST in siRNA GAL2 receptor or in GAL1 receptor KD rats. In the OFT the 
same pattern of response was observed, since GAL(1-15) did not affect neither 
number of entries as the time spent in the central square of open field in GAL2 
receptor or in GAL1 receptor KD rats (Millon et al., 2015).
The fact that GAL1 and GAL2 receptors are needed to obtain GAL(1-15)-effect 
confirms the hypothesis that GAL(1-15) preferring sites may be formed through 
the formation of GAL1/GAL2 heteroreceptor complexes which lead to 
conformational changes in their GAL recognition sites converting GAL1 and/or 
GAL2 receptors into GAL recognition fragment preferring binding sites with 
reduced affinity for GAL (Fuxe et al., 2008; Fuxe et al., 2012). In recent work, 
Borroto-Escuela et al. analyzed the existence of GAL1/GAL2 heteroreceptor 
complex in co-transfected HEK cells through Bioluminescence Resonance 
Energy Transfer (BRET2) giving evidence for the existence of GAL1/GAL2 
heteroreceptor complexes (Borroto-Escuela et al., 2014). A differential role of 
GAL and GAL(1-15) in signaling cascades Gi/o-Adenylate cyclase (AC)-Protein 
kinase A (PKA) and Gq-Phospholipase C (PLC)-Protein kinase C (PKC)/Ca2+ 
was observed with cyclic adenosine monophosphate response element (CRE) 
and nuclear factor of activated T-cells (NFAT) -luciferase reporter gene assays 
in co-expressing GAL1 and/or GAL2 receptors HEK293T cells (Borroto-Escuela 
et al., 2014).
The formation of GAL1/GAL2 heteroreceptor complexes with high affinity 
for GAL(1-15) can help explain the fact that GAL(1-15) induces a stronger 
action than GAL at the behavioral level. As described is this review GAL2 
receptor may induce antidepressant actions via Gq/G11 mediated GAL2 
receptor signaling. It seems possible that in the GAL1/GAL2 heteroreceptor 
complex the GAL2 receptor protomer signals in a different way upon activation 
by its preferred ligand GAL(1-15) leading to its strong depression-like action. 
Alternatively, the GAL(1-15) activation of the GAL1 receptor protomer may via 
an allosteric receptor-receptor interaction inhibit the Gq/G11 mediated signaling 
of the GAL2 receptor protomer and switch it towards Gi/o mediated signaling. In 
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this way both GAL1 and GAL2 receptors protomers become coupled to Gi/o 
which may lead to the strong depression-like actions observed with GAL(1-15) 
(Millon et al., 2015). The formation of homodimers and heterodimers among 
neuropeptide receptors is known (AbdAlla et al., 2005). GAL1 receptor can form 
homodimers (Wirz et al., 2005) and heterodimers with 5-HT1A receptors 
(Borroto-Escuela et al., 2010; Fuxe et al., 2012) and likely with other G-protein 
coupled receptors. 
The existence of GAL1/GAL2 heteroreceptors complexes in brain tissue was 
demonstrated with in situ Proximity Ligation Assay (PLA) to analyze the 
proximity of GAL1 and GAL2 receptors in the dorsal hippocampus and DR nuclei 
of the KD rats of GAL2 receptor (Millon et al., 2015). In the siRNA GAL2 receptor 
treated animals, PLA- positive red clusters were still observed in the dorsal 
hippocampus and DR (Millon et al., 2015). However, the number of GAL1/GAL2 
complex was reduced by 40% in CA1, CA2 and dentate gyrus in dorsal 
hippocampus and by 60% in the DR nucleus compared with the vehicle group 
(Millon et al., 2015). In agreement with these results, in the siRNA GAL2 
receptor treated animals the colocalization of GAL1 and GAL2 receptors was 
reduced in the both areas (Millon et al., 2015).
These results strongly indicate that the PLA signals obtained are specific and 
represent the GAL1 and GAL2 heteroreceptor complex. This reduction of the 
PLA signal was sufficient to block the depression- and anxiogenic-like effects of 
GAL(1-15), linking them to its actions at the GAL1/GAL2 heteroreceptor complex 
(Millon et al., 2015). 
Effects of Galanin on monoamine systems
The physiological/ pathophysiological mechanisms underlying the action(s) of 
GAL most probably involves modulation of monoaminergic systems, in 
particular, the LC and DR nuclei. This was further supported by the fact that all 
three receptors are found in the DR and LC of rats (O'Donnell et al., 1999; 
Burazin et al., 2000; Mennicken et al., 2002) and that GAL is co-expressed in 
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almost 40% of the serotonergic neurons in the DR (Xu et al., 1997) and in 
around 80% of the noradrenergic neurons in the LC (Holets et al., 1988).
I.c.v. GAL produced a reduction in basal NA release in the ventral hippocampus 
of the awake rat measured by microdialysis, and, significantly attenuated the 
increase of extracellular hippocampal NA levels evoked by desipramine 
(Yoshitake et al., 2003). These effects could involve the LC since GAL inhibits 
LC firing and produces an outward current in rat brain slices through GAL1-3 
receptors. The application of GAL1-3 receptor agonist M961, but not GAL2  
receptor agonist AR-M1896, caused hyperpolarisation of these LC neurons 
(Seutin et al., 1989; Sevcik et al., 1993; Pieribone et al., 1995; Ma et al., 2001). 
Moreover, Grenhoff et al. (Grenhoff et al., 1993) observed that ‘‘burst’’ firing of 
LC neurons (i.e., rapid firing of LC) released GAL from terminals on axons of LC 
neurons projecting to the VTA, and that the hyperpolarizing influence of GAL on 
dopamine (DA) cell bodies in the VTA decreased the activity of these DA 
neurons. This finding suggested that the hyperactivity of LC neurons observed 
in depression might bring about such depression-related responses by 
decreasing the neural activity of dopaminergic cell bodies in the VTA as the 
result of GAL released from LC-derived terminals in the VTA (Weiss et al., 
1998).
In relation with the DR and the 5-HT system, i.c.v. GAL reduced 5-HT 
metabolism in ventral limbic cortex, hippocampal formation, and fronto-parietal 
cortex probably via direct inhibitory action on DR nerve cells reducing their firing 
rates (Fuxe et al., 1988b). This result is in agreement with other works where 
i.c.v. GAL into vecinity of the DR caused a dose-related and long-lasting 
inhibition of 5-HT release in the ventral hippocampus measured by microdialysis 
(Kehr et al., 2002). Moreover, immunohistochemistry experiments showed a 
strong GAL immunoreactivity staining was observed in the DR after GAL 
administration, suggesting that the DR was the site of action of GAL on 
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hippocampal 5-HT release (Kehr et al., 2002). In agreement, i.c.v. GAL 
attenuates the increase in extracellular levels of 5-HT induced by SSRI 
citalopram, indicating that this inhibitory action persisted under conditions of 
serotonergic activation following reuptake inhibition by an SSRI (Yoshitake et al., 
2003; Kuteeva et al., 2008). Electrophysiological experiments, where GAL 
inhibits the firing rate of 5-HT neurons, probably via G protein-coupled inwardly-
rectifying potassium channel (GIRK) (Xu et al., 1998), could support these 
findings.
The 5-HT1A receptor seems to be a key receptor in the GALR-5-HT interaction. 
In the DR, i.c.v. GAL induced a time-dependent reduction in affinity and an 
increase in the 5-HT1A autoreceptor density (Razani et al., 2000). At post-
synaptic level GAL reduced the affinity of the 5-HT1A receptors in the ventral 
limbic cortex (Fuxe et al., 1988a; Hedlund et al., 1996). Moreover, in 
hypothermia, locomotor activity and passive avoidance, i.c.v. GAL blocked post-
synaptic 5-HT1A receptor function (Misane et al., 1998; Razani et al., 2001; 
Kehr et al., 2002). This interaction can in part be due to the existence of GAL1-
5-HT1AR heteroreceptor complexes in discrete brain regions (Borroto-Escuela 
et al., 2010) 
The GAL(1-15) also modified 5-HT system (Millon et al., 2015). Using a rat 
medullary raphe-derived cell line RN33B, we observed that GAL(1-15) 
significantly decreased the 5-HT immunoreactivity in the RN33B cells (p<0.001) 
(Fig.2). Interestingly this reduction was stronger than the one induced by GAL 
(p<0.001) (Fig.2) (Millon et al., 2015). This effect of GAL(1-15) on 5-HT 
immunoreactivity may indicate a possible mechanism contributing to the 
depression-like actions of GAL(1-15).
In this cell model, we have detected PLA- positive clusters, indicating close 
proximity of GAL1 and GAL2 receptors and the possible formation of 
GAL1/GLAR2 heteroreceptor complexes (Millon et al., 2015). Therefore, the 
formation of GAL1/GAL2 heteroreceptor complexes with high affinities for 
GAL(1-15) can help explain the fact that GAL(1-15) induces a stronger action 
than GAL in the reduction of 5-HT in the RN33B. Thus, the strong decrease on 
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5-HT immunoreactivity induced by GAL(1-15) may indicate a mechanism 
contributing to the depression- like actions of GAL(1-15) (Fig. 2D)  (Millon et al., 
2015). Recently, we have described that GAL(1–15) enhances the 
antidepressant effects induced by 8-hydroxy-2-(di-n-propylamino) tetralin (8-
OH-DPAT) acting on 5-HT1A receptors operating as postjunctional or as 
autoreceptors, confirming the importance of the interaction GALR-5-HT1A 
receptors (Millon et al., 2016).
Conclusion
All these data emphasized the role of GAL and its N-Terminal fragment (1-15) in 
depression. Moreover, GAL(1-15) induces a stronger depressive effect than 
GAL through GAL1-GAL2 heteroreceptor complexes in the raphe-limbic system. 
Since 5-HT, especially through 5-HT1A, and GAL receptors interact at both pre-
and postsynaptic level, the development of drugs targeting potential GAL1-
GAL2-5-HT1A heteroreceptor complexes linked to the raphe-hippocampal 5-HT 
neurons may represent new treatment in depression.
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Figure 1. Expression levels of GAL2 receptor mRNA (A) and GAL1 receptor 
mRNA (C) in dorsal hippocampus. (A,B) Expression levels of mRNA GAL2 or 
GAL1 receptors (4 rats per group) measured on different days after 
administration of the Acell smart pool siRNA for GAL2 receptor and (C,D) 
expression levels of mRNA GAL2 receptor or GAL1 receptor (4 rats per group) 
measured on different days after administration of the Acell smart pool siRNA 
for GAL1 receptor. The quantitative PCR results were normalized to the 
expression levels of GAPDH and expressed as arbitrary units. *p<0.05, 
**p<0.01 vs Vehicle according to  student´s t-test. Modified from (Millon et al., 
2015).
Figure 2. Close proximity between Galanin receptor 1 (GAL1 receptor) and 
Galanin receptor 2 (GAL2 receptor) and their effects in 5-HT synthesis and 
storage in RN33B cells. (A) Detection of close proximity between GAL1-GAL2 
receptors in RN33B cells by in situ PLA. Scale bar, 10 μm. (B) Quantification of 
5-HT immunoreactivity was analyzed after incubation with GAL and GAL(1-15) 
***p<0.001 according to one-way ANOVA followed by Newman Keuls Multiple 
Millón et al., 2016 Neuropeptides
25
Comparison Test. (C) Representative images of 5-HT stained RN33B cells 
under different conditions are presented. Scale bar, 10 μm. Modified from 
(Millon et al., 2015). (D) Representative schema illustrating the reduction of 5-
HT in the dorsal raphe nuclei induced by the action of GAL(1-15) through the 
GAL1/GAL2 heteroreceptor complexes. Representative projections from DR to 
cortico-limbic areas are shown in red. 
Figure 1 


























































































































































































Ligand Model Specie Route Effect Reference
Galanin receptor ligand
Galanin FST Rat VTA  Weiss et al., 1998
FST Rat i.c.v.  Kuteeva et al., 2007
Galnon FST Rat i.p.  Lu et al., 2005
Galmic FST Rat i.p.  Barfai et al., 2004
M617 (GAL1 receptor agonist) FST Rat i.c.v.  Kuteeva et a., 2008
SNAP37889 
(GAL3 receptor antagonist)
FST Rat i.p.  Swanson et al., 2005
GAL3  receptor antagonist TST Mouse i.p.  Barr et al., 2006
FST Rat i.p.  Barr et al., 2006
AR-M1896 
(GAL2/3 receptor agonist)
FST Rat i.c.v.  Kuteeva et al., 2008
M871 (GAL2 receptor 
antagonist)
FST Rat i.c.v.  Kuteeva et al., 2008
M1160 (GAL2 receptor 
agonist)
TST Mouse i.c.v.  Saar et al., 2013a
J18 (GAL2 receptor agonist) FST Mouse i.v.  Saar et al., 2013b
GAL(1-15) FST Rat i.c.v.  Millon et al., 2015
TST Rat i.c.v.  Millon et al., 2015
OFT Rat i.c.v. * Millón et al., 2015




FST   Mouse  Kuteeva et al., 2005
GAL overexpressing 
(GalOE-D)
TST Mouse 0 Holmes et al., 2005
GAL1-KO TST Mouse 0 Holmes et al., 2005
EPM Mouse * Holmes et al., 2003
GAL2-KO EPM Mouse * Bailey et al., 2007
TST Mouse 0 Gottsch et al., 2005
GAL2 receptor overexpressing FST Mouse  Le Maitre et al., 2011
GAL3-KO TST Mouse 0 Brunner et al., 2014
FST Mouse 0 Brunner et al., 2014
EPM Mouse * Brunner et al., 2014
OFT Mouse * Brunner et al., 2014
L/D test Mouse * Brunner et al., 2014
GAL1-KD FST Rat 0 Millon et al., 2015
OFT Rat 0 Millon et al., 2015
GAL2-KD FST Rat 0 Millon et al., 2015
OFT Rat 0 Millon et al., 2015
Table 1. Effects of Galanin receptor ligands and genetic animal models in rodent test of 
depression. FST: Forced Swimming Test; TST: Tail Suspension Test; OFT: Open Field Test; 
EPM: Elevated Plus Maze; L/D Test: Ligth-Dark test; VTA: Ventral Tegmentar Area; i.c.v.: 
intracerebroventricular; i.p.: intraperitoneal; i.v.: intravenous; KO: Knock Out; KD: Knock Down; 
: pro-depressive effect; 0: no effect; : antidepressant effec; *: anxiogenic effect.
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GALANIN (1-15) AND THE HETERODIMER 
GALR1/GALR2 IN DEPRESSION AND ANXIETY-
LIKE BEHAVIOURS
Carmelo Millón1*, Antonio Flores-Burgess1, Manuel Narváez1, Dasiel O. 
Borroto-Escuela2, Belén Gago1, Luis Santín3, Estela Castilla-Ortega3, José 
Ángel Narváez1, Kjell Fuxe2 & Zaida Díaz-Cabiale1.
Abstract
Galanin is a 29 amino acid neuropeptide widely distributed in neurons within the 
central nervous system. Galanin exerts its biological activities through three 
different G protein-receptors and participates in a number of functions, including 
mood regulation. Not only Galanin but also Galanin N-terminal fragments like 
Galanin(1-15) are active at the central level. In this work, we review the latest 
findings in studies on Galanin and Galanin(1-15) in depression-related 
behaviours. Our focus is on animal models for depression, and we pay some 
attention to research data obtained in human studies. Since Serotonin (5-HT), 
especially through 5-HT1A, and Galanin receptors interact at both pre-and 
postsynaptic level, the development of drugs targeting potential GAL1-GAL2-5-
HT1A heteroreceptor complexes linked to the raphe-hippocampal 5-HT neurons 
may represent new treatment strategies in depression.
Key words: depression, galanin
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Highlights
 GAL(1-15) produces depression- and anxiety- like eects in behavioural test.
 In these tests, GAL(1-15) induces stronger eects than GAL.
 GALR1/GALR2 heteroreceptor complexes are involved in GAL(1-15)-mediated 
ac&on.
